Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes 16 RNAi-Related Patent Applications

Premium
Title: Gene Silencing         
 
Number: 20060218673
 
Filed: Oct. 12, 2004
 
Inventor: Milo Aukerman, Pioneer Hi-Bred International
 
“The invention provides methods and compositions useful in target sequence suppression and target sequence validation,” according to the patent application’s abstract. “The invention provides polynucleotide constructs useful for gene silencing, as well as cells, plants and seeds comprising the polynucleotides. The invention also provides a method for using microRNA to silence a target sequence.”
 

 
Title: siRNA-Mediated Gene Silencing in Transgenic Animals         
 
Number: 20060218654
 
Filed: Oct. 10, 2003 PCT Filed: Oct. 10, 2003
 
Lead Inventor: Jost Seibler, Artemis Pharmaceuticals
 
According to the patent application’s abstract, the invention “relates to a process that enables constitutive and inducible gene knock down in living organisms using a short hairpin RNA expression vector integrated into the genome of the organism.”
 

 
Title: Antisense Oligonucleotide Modulation of STAT3 Expression         
 
Number: 20060217339
 
Filed: March 15, 2006
 
Inventor: James Karras, Eli Lilly
 
The patent application, its abstract states, covers “compounds, compositions and methods … for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided, it adds. “Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Numbers: 20060217337, 20060217336, 20060217335, and 20060217334
 
Filed: Feb. 21, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics
 
According to the patent applications’ abstracts, the inventions concern “methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the [inventions relate] to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: RNA Interference-Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid         
 
Number: 20060217332
 
Filed: Dec. 9, 2005
 
Lead Inventor: Chandra Vargeese, Sirna Therapeutics
 
“This invention relates to compounds, compositions, and methods useful for modulating VEGF and/or VEGFR gene expression using short interfering nucleic acid molecules,” according to the patent application’s abstract. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of VEGF and/or VEGFR gene expression and/or activity by RNA interference using small nucleic acid molecules. … The application also relates to methods of treating diseases and conditions associated with VEGF and/or VEGFR gene expression, such as ocular diseases and conditions, including age-related macular degeneration and diabetic retinopathy, as well as providing dosing regimens and treatment protocols.”
 

 
Title: Chemically Modified Double-Stranded Nucleic Acid Molecules that Mediate RNA Interference         
 
Number: 20060217331
 
Filed: Dec. 8, 2005
 
Lead Inventor: Chandra Vargeese, Sirna Therapeutics
 
“This invention relates to compounds, compositions, and methods useful for modulating gene expression using chemically modified double stranded nucleic acid molecules,” according to the patent application’s abstract. “In particular, the … invention features double-stranded nucleic acid molecules … and methods used to modulate the expression of genes via RNA interference. The invention features various modifications to double-stranded nucleic acid structures, including chemically modified overhangs and optimized stabilization motifs of guide strand and passenger strands of double stranded nucleic acid molecules that allow for potent RNA interference in therapeutically relevant applications.”
 

 
Title: Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs         
 
Number: 20060217330
 
Filed: Dec. 9, 2005
 
Lead Inventor: Gunther Hartmann, University of Bonn (Alnylam Pharmaceuticals)
 
The “invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals,” the patent application’s abstract states.
 

 
Title: Therapeutic Uses of Inhibitors of RTP801         
 
Number: 20060217329
 
Filed: Aug. 16, 2005
 
Inventor: Elena Feinstein, Quark Biotech
 
According to the patent application’s abstract, the invention “provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.”
 

 
Title: siRNA Expression System         
 
Number: 20060217327
 
Filed: July 9, 2004 PCT Filed: July 9, 2004
 
Lead Inventor: Irene Bozzoni, University of Rome La Sapienza
 
The invention, the patent application’s abstract states, comprises “an expression system for the correct, stable, and effective expression in mammalian cells of a siRNA comprising: a polymerase H RNA-dependent promoter derived from the U1 RNA gene; downstream from the sequence; suitable restriction sites for the cloning of the sequence transcribing the pre-siRNA downstream from these sites; [and] sequences derived from the sequences at 3' of the gene for U1 snRNA that are necessary and sufficient for the correct formation of 3' of the presiRNA.”
 

 
Title: Method of Obtaining an Enriched Population of siRNA-Expressing Cells         
 
Number: 20060216823
 
Filed: June 1, 2006
 
Lead Inventor: Vincente Planelles, University of Utah
 
“Problems with transience of siRNA-mediated knock-down and transfection efficiency have limited the scope of RNAi-based experiments,” according to the patent application’s abstract. “The invention provides a tool for employing RNAi more efficiently and effectively by integrating RNAi expression with methods of cell enrichment.”
 

 
Title: Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Uses Thereof         
 
Number: 20060217326
 
Filed: Dec. 16, 2003 PCT Filed: Dec. 16, 2003
 
Lead Inventor: Zhiwen Zhou
 
“The invention provides a group of nucleic acid fragments … for prevention of HIV infection or AIDS and the usage thereof,” the patent application’s abstract states. “In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The double-stranded RNA derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus that carry DNA … RNA infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.”
 

 
Title: RNAi Modulation of the Nogo-L or Nogo-R Gene and Uses Thereof         
 
Number: 20060217324
 
Filed: Jan. 24, 2006
 
Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals
 
“The invention relates to compositions and methods for modulating the expression of Nogo-L or Nogo-R genes, and more particularly to the down regulation of Nogo-L or Nogo-R by chemically modified oligonucleotides,” the patent application’s abstract states.
 

 
Title: RNA Interference-Mediated Inhibition of Checkpoint Kinase-3 Gene Expression Using Short Interfering Nucleic Acid
 
Number: 20060216747
 
Filed: June 6, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics
 
According to the patent application’s abstract, “this invention relates to compounds, compositions, and methods useful for modulating checkpoint kinase gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of checkpoint kinase gene expression and/or activity by RNA interference using small nucleic acid molecules.”